ArticleCase reports in rheumatology2017
Effective Administration of Rituximab in Anti-MDA5 Antibody-Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review.
Article in Case reports in rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.Frontiers in immunology · 2021Pooled it
- Subcutaneous Emphysema and Severe Interstitial Lung Disease in the Setting of Anti-MDA 5 Positive Dermatomyositis in a Hispanic Patient.Case reports in rheumatology · 2025Article
- Case Report: Telitacicept for interstitial lung disease associated with idiopathic inflammatory myopathies: an observational study.Frontiers in pharmacology · 2025Article
- Management of anti-melanoma differentiation-associated gene 5 antibody-induced refractory dermatomyositis complicated by interstitial pneumonia using tofacitinib and its outcomes: a case report.Journal of medical case reports · 2024Article
- The central helicase domain holds the major conformational epitopes of melanoma differentiation-associated gene 5 autoantibodies.Rheumatology (Oxford, England) · 2024Article
- Utility of Myositis-Specific Autoantibodies for Treatment Selection in Myositis.Current treatment options in rheumatology · 2022Article
- Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications.Nature communications · 2022Article
- Anti-MDA5 Amyopathic Dermatomyositis-A Diagnostic and Therapeutic Challenge.Life (Basel, Switzerland) · 2022Article
- Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.Frontiers in immunology · 2022Article
- Off-Label Uses of Rituximab in Dermatology.Current dermatology reports · 2022Review
- Idiopathic inflammatory myopathies.Nature reviews. Disease primers · 2021Article
- Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy.Clinical rheumatology · 2021Article
- Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases.BMJ case reports · 2021Article
- Management of Myositis-Associated Interstitial Lung Disease.Medicina (Kaunas, Lithuania) · 2021Review
- Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease.Drugs in context · 2021Review
- Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies.Frontiers in immunology · 2021Review
- Juvenile dermatomyositis resembling late-stage Degos disease with gastrointestinal perforations successfully treated with combination of cyclophosphamide and rituximab: case-based review.Rheumatology international · 2020Review
- Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease.Seminars in arthritis and rheumatism · 2020Article
- Macrophage activation syndrome in adult dermatomyositis: a case-based review.Rheumatology international · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe the case of a 48-year-old man with dermatomyositis (DM) who demonstrated rapidly progressive interstitial lung disease (RP-ILD) and refractory cutaneous involvement together with high levels of anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5-Ab). Even after combination immunosuppressive therapy including a corticosteroid, cyclosporine A, and intravenous cyclophosphamide, his respiratory insufficiency and cutaneous involvement progressively worsened. However, the administration of rituximab (RTX) resulted in clinical remission as well as a visible reduction in anti-MDA5-Ab levels, suggesting that RTX could be a useful remedy in cases refractory to conventional immunosuppressive agents, especially those of RP-ILD related to anti-MDA5-Ab-positive DM.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.